Supporting Information

Copper Catalyzed Oxidative Coupling of Amines with Formamides: A New Approach for the Synthesis of Unsymmetrical Urea Derivatives

G. Sathish Kumar, R. Arun Kumar, P. Santhosh Kumar, N. Veera Reddy, K. Vijaya Kumar, M. Lakshmi Kantam, S. Prabhakar and K. Rajender Reddy

Inorganic and Physical Chemistry Division, Indian Institute of Chemical Technology, Tarnaka, and Hyderabad 500 607, India, Fax: +91-040-27160921. e-mail: <u>rajender@iict.res.in</u>; <u>rajenderkallu@yahoo.com</u>

Table of Contents

1. General Information	2
2. Optimization studies	.3
3. Experimental section	.4
4. Spectroscopic data for products	.5
5. Copies of ¹ H, ¹³ C, ESI & HRMS spectra for products	.14
6. HPLC data for the 3k & 3l compounds	70

1. General Information :

All chemicals were purchased from Sigma-Aldrich and S.D Fine Chemicals, AVRA chemicals Pvt. Ltd. India and used as received. ACME silica gel (100–200 mesh) was used for column chromatography and Thin layer chromatography (TLC) was carried out on TLC Silica gel 60 F_{254} and compounds were visualized by UV light, I_2 vapors, phosphomolybdic acid stain, ninhydrin stain. All the other chemicals and solvents were obtained from commercial sources and purified using standard methods.. The IR values are reported in reciprocal centimeters (cm⁻¹). All ¹H, ¹³C {¹H} NMR spectra were recorded on a Avance-300, Inova-400, Inova-500 MHz Spectrometer. Chemical shifts (δ) are reported in ppm, using TMS (δ =0) as an internal standard in CDCl₃. The peak patterns are indicated as follows: s, singlet; d, doublet; t, triplet; q, quintet; dd, doublet of doublet; dt, doublet of triplet. The coupling constants (*J*), are reported in Hertz (Hz). Mass spectral data were compiled using MS (ESI), HRMS mass spectrometers. HPLC data recorded on SHIMAZDU HPLC Instrument equipped with DIODE ARRAY detector; Mobile phase: methanol :water = 90% +10% (1.5% acetic acid in HPLC water); Flow rate: 0.5 ml/min.; Column: LUX5M AMYLOSE-2 (phenomenox).; UV-range : 190 nm.

2.Optimization of raction conditions : ^a

$ \begin{array}{c} & & & \\ & & & & \\ & & & & \\ & & & \\ & & & & & \\ & & & & \\ & & & & \\ & & & & & \\ & & & & & \\ & & & & & \\ & & & & & \\ & & & & & \\ & & & & & \\ & & & & & \\ & & & & & \\ & & & & & \\ & & $					
entry	catalyst	Oxidant	Reaction time	yield ^b (%)	
1	Cul	TBHP in Decane	4 h	48	
2	CuBr	TBHP in Decane	4 h	47	
3	CuCl	TBHP in Decane	4 h	43	
4	CuBr ₂	TBHP in Decane	4 h	64	
5	CuCl ₂	TBHP in Decane	4 h	45	
6	Cu(CH ₃ COO) ₂	TBHP in Decane	4 h	24	
7	CuBr ₂	TBHP in Water	4 h	55	
8	CuBr ₂	H ₂ O ₂	4 h	N.R	
9	CuBr ₂	ТВРВ	4 h	N.R	
10	CuBr ₂	TBP	4 h	N.R	
11	CuBr ₂	TAP	4 h	N.R	
12	CuBr ₂	-	4 h	N.R	
13	-	TBHP in Decane	4 h	N.R	
14	CuBr ₂	TBHP in Decane	24 h	55	
15	CuBr ₂	TBHP in Decane	1 h	65	
16 ^c	CuBr ₂	TBHP in Decane	1 h	52	
17 ^d	CuBr ₂	TBHP in Decane	1 h	59	

^a Reaction conditions: **1a** (1 equiv), catalyst (5 mol%), DMF **2a** (2 mL, 27 equiv.), Oxidant (1.5 equiv.), r.t., 4 h. ^b Isolated yields. ^c 20 equivalents of DMF has taken in 2 mL of CH₃CN solvent and reaction time 1 h. ^d 0.2 mL of pyridine was added as an additive.

2. Experimental section:

General procedure for the synthesis of aliphatic urea derivatives (Scheme 2, 3a-3v).

A solution of Amine (1a-l) (1.0 mmol), CuBr₂ (11 mg, 5 mol%) in 2 mL of the respective formamide (2ad) was stirred at room temperature. To the same solution, a 5-6 M TBHP solution in decane (1.5 mmol) was added drop wise and stirred for 1hr. After completion of reaction time, formamide was either evaporated was removed under reduced pressure or directly proceeded for the conventional work up with ethyl acetate water mixture. The organic layer was separated and dried over anhydrous Na₂SO₄. Removal of the solvent under reduced pressure afforded the crude product, which was purified by column chromatography on silica gel (hexane/ethyl acetate 4:6).

General procedure for the synthesis of aromatic or hetero aromatic ureas (Scheme 3, 5a-5f).

A solution of 2-carbonyl-substituted anilines (4**a-f**) (1.0 mmol), $Cu(OTf)_2$ (18 mg, 5 mol%) in 2 mL of dimethyl formamide **2a** was stirred at room temperature. To the same solution, 5-6 M TBHP solution in decane (1.5 mmol) was added drop wise, temperature raised to 80° C, and stirred for 3 h. After cooling to room temperature, the reaction mixture was extracted with ethyl acetate and dried over anhydrous Na₂SO₄. Removal of the solvent under reduced pressure afforded the crude product, which was purified by column chromatography on silica gel (hexane/ethyl acetate 8:2).

4. Spectroscopic data for the products:



N, *N*-dimethyl-4-phenylpiperidine-1-carboxamide : (scheme 2, entry1, 3a)

Isolated yield = 65%; IR cm⁻¹: 2931, 1643, 1491, 1451, 1392, 1193, 1064, 904, 757, 700. ¹H NMR $\delta(300 \text{ MHz}, \text{CDCl}_3)$ 7.18 – 7.33 (m, 5H), 3.75 – 3.84 (m, 2H), 2.81 – 2.9 (m, 8H), 2.66 (tt, *J* = 3.7, 11.8 Hz, 1H), 1.82 – 1.91 (m, 2H), 1.63 – 1.76 (m, 2H). ¹³C NMR δ (75 MHz, CDCl3): 165, 145.7, 128.3, 126.6, 126.2, 47.4, 42.8, 38.4, 33.1. MS (ESI): m/z = 233 (M+H)⁺. HRMS ESI (M+H)⁺ m/z calcd for C₁₄H₂₁N₂O (M+H)⁺ = 233.16484, found = 233.16449.



1, 1, 3-trimethyl-3-phenethylurea : (scheme 2, entry 2, 3b)

Isolated yield = 52% ; IR cm⁻¹: 2926, 1641, 1496, 1454, 1383, 1167, 1122, 747, 700. ¹H NMR $\delta(300 \text{ MHz}, \text{CDCl}_3)$ 7.28-7.3 (m, Ar, 2H), 7.18-7.24 (m, Ar, 3H), 3.4 (t, *J* = 7.5 Hz, 2H), 2.85 (t, *J* = 7.5 Hz, 2H), 2.81 (s, 3H), 2.74 (s, 6H). ¹³C NMR $\delta(75 \text{ MHz}, \text{CDCl}_3)$: 165.1, 139.2, 128.5, 128.2, 126, 51.7, 38.4, 36.8, 33.9. MS (ESI): m/z = 207 (M+H)⁺. HRMS ESI (M+H)⁺ m/z calcd for C₁₂H₁₉N₂O (M+H)⁺ = 207.14919, found = 207.14900.



4-benzyl-N, N-dimethylpiperidine-1-carboxamide : (scheme 2, entry 3, 3c)

Isolated yield = 49% ; IR cm⁻¹: 2922, 2848, 1643, 1493, 1449, 1393, 1059, 746, 701. ¹H NMR δ (300 MHz, CDCl₃) 7.28-7.34 (m, Ar, 2H), 7.12-7.21 (m, Ar, 3H), 3.61-3.66 (m, 2H), 2.8 (s, 6H), 2.62-2.72 (m, 2H), 2.54 (d, *J* = 6.7 Hz, 2H), 1.59-1.71 (m, 3H), 1.15-1.28 (m, 2H). ¹³C NMR δ (75 MHz,

CDCl3): 165, 140.1, 128.9, 128, 125.7, 46.9, 43, 38.4, 38.2, 31.8. MS (ESI): $m/z = 247 (M+H)^+$.HRMS ESI $(M+H)^+$ m/z calcd for $C_{15}H_{23}N_2O (M+H)^+ = 247.18049$, found = 247.17982.



N, N, 4-trimethylpiperidine-1-carboxamide : (scheme 2, entry 4, 3d)

Isolated yield = 36% ; IR cm⁻¹: 2923, 1644, 1493, 1450, 1393, 1135, 1060, 970. ¹H NMR δ (300 MHz, CDCl₃) 3.6-3.65 (m, 2H), 2.8 (s, 6H), 2.71 (td, *J* = 2.4, 13 Hz, 2H), 1.6-1.65 (m, 2H), 1.44-1.54 (m, 1H), 1.14 (qd, *J* = 3.9, 12.8 Hz, 2H), 0.94 (d, *J* = 6.4 Hz, 3H). ¹³C NMR δ (75 MHz CDCl3): 165.1, 47, 38.4, 33.9, 31.1, 21.7. MS (ESI): m/z = 171 (M+H)⁺. HRMS ESI (M+H)⁺ m/z calcd for C₉H₁₉N₂O (M+H)⁺ = 171.14919, found = 171.14894.



1, 1-dibutyl-3,3-dimethylurea : (scheme 2, entry 5, 3e)

Isolated yield = 29% ; IR cm⁻¹: 2957, 2929, 1648, 1490, 1398, 1200, 1138. ¹H NMR δ (300 MHz, CDCl₃) 3.09 (t, *J* = 6.9 Hz, 4H), 2.76 (s, 6H), 1.46 (p, *J* = 6.9 Hz, 4H), 1.22-1.3 (m, 4H), 0.89 (t, *J* = 6.9 Hz, 6H). ¹³C NMR δ (75 MHz, CDCl₃): 165.5, 47.7, 38.6, 30, 20, 13.7. MS (ESI): m/z = 201 (M+H)⁺. HRMS ESI (M+H)⁺ m/z calcd for C₁₁H₂₅N₂O (M+H)⁺ = 201.19614, found = 201.19582.



N,N-dimethylpyrrolidine-1-carboxamide : (scheme 2, entry 6, 3f)

Isolated yield = 21% ; IR cm⁻¹: 2930, 2873, 1632, 1453, 1387, 1347, 1064, 777. ¹H NMR δ (300 MHz, CDCl₃) 3.3-3.37 (m, 4H), 2.83 (s, 6H), 1.79-1.84 (m, 4H). ¹³C NMR δ (75 MHz, CDCl₃): 163.5, 48.3, 38.1, 25.4. MS (ESI): m/z = 143 (M+H)⁺. HRMS ESI (M+H)⁺ m/z calcd for C₇H₁₅N₂O (M+H)⁺ = 143.11789, found = 143.11758.



N, N-dimethylmorpholine-4-carboxamide : (scheme 2, entry 7, 3g)

Isolated yield = 34%; IR cm⁻¹: 2854, 1643, 1494, 1392, 1203, 1115, 895. ¹H NMR δ (300 MHz, CDCl₃) 4.26 (m, 1H), 3.69 (t, *J* = 4.9 Hz, 4 H), 3.23 (t, *J* = 4.9 Hz, 4 H), 2.84 (s, 6H). ¹³C NMR δ (75 MHz, CDCl₃): 164.5, 66.4, 47, 38.1. MS (ESI): m/z = 159 (M+H)⁺. HRMS ESI (M+H)⁺ m/z calcd for C₇H₁₅N₂O₂ (M+H)⁺ = 159.11280, found = 159.11266.



N, N-dimethyl-4-phenylpiperidine-1-carboxamide : (scheme 2, entry 8, 3h)

Isolated yield = 63%; IR cm⁻¹: 2971, 2931, 1641, 1418, 1374, 1274, 1243, 755, 700. ¹H NMR δ (300 MHz, CDCl₃) 7.3 (t, *J* = 6.9 Hz, 2H), 7.18-7.22 (m, Ar, 3H), 3.74-3.76 (m, 2H), 3.22 (q, *J* = 6.9 Hz, 4H), 2.85 (td, *J* = 2, 12.9 Hz, 2H), 2.65 (tt, *J* = 3.9, 11.9 Hz, 1H), 1.81-1.87 (m, 2H), 1.7 (qd, *J* = 3.9, 11.9 Hz, 2H), 1.13 (t, *J* = 6.9 Hz, 6H). ¹³C NMR δ (75 MHz, CDCl3): 164.8, 145.8, 128.4, 126.7, 126.2, 47.8, 42.9, 41.7, 33.1, 13.2. MS (ESI): m/z = 261 (M+H)⁺. HRMS ESI (M+H)⁺ m/z calcd for C₁₆H₂₅N₂O (M+H)⁺ = 261.19614, found = 261.19571.



1,1-diethyl-3-methyl-3-phenethylurea : (scheme 2, entry 9, 3i)

Isolated yield = 58%; IR cm⁻¹: 2971, 2931, 1641, 1486, 1398, 1121, 983, 748, 700. ¹H NMR δ (300 MHz, CDCl₃) 7.17-7.3 (m, Ar, 5H), 3.39 (t, *J* = 7.5 Hz, 2H), 3.1 (q, *J* = 6.9 Hz, 4H), 2.85 (t, *J* = 7.9 Hz, 2H), 2.81 (s, 3H), 1.06 (t, *J* = 6.9 Hz, 6H). ¹³C NMR δ (75 MHz, CDCl₃): 164.9, 139.4, 128.6, 128.3, 126.1, 52, 41.9, 37, 34, 13.1. MS (ESI): m/z = 235 (M+H)⁺. HRMS ESI (M+H)⁺ m/z calcd for C₁₄H₂₃N₂O (M+H)⁺ = 235.18049, found = 235.18019.



4-benzyl-N, N-diethylpiperidine-1-carboxamide : (scheme 2, entry 10, 3j)

Isolated yield = 53%; IR cm⁻¹: 2926, 1642, 1416, 1373, 1250, 964, 745, 700. ¹H NMR $\delta(300 \text{ MHz}, \text{CDCl}_3)$ 7.25-7.3 (m, Ar, 2H), 7.18-7.21 (m, Ar, 1H), 7.12-7.15 (m, Ar, 2H), 3.57-3.62 (m, 2H), 3.17 (q, *J* = 6.7 Hz, 4H), 2.66 (td, *J* = 2.2, 12.8 Hz, 2H), 2.54 (d, *J* = 6.7 Hz, 2H), 1.59-1.7 (m, 3H), 1.18-1.28 (m, 2H), 1.1 (t, *J* = 6.7 Hz, 6H). ¹³C NMR $\delta(75 \text{ MHz}, \text{CDCl}_3)$: 164.7, 140.1, 128.9, 128.1, 125.7, 47.3, 43.1, 41.7, 38.3, 31.9, 13.1. MS (ESI): m/z = 275 (M+H)⁺. HRMS ESI (M+H)⁺ m/z calcd for C₁₇H₂₇N₂O (M+H)⁺ = 275.21179, found = 275.21118.



Morpholino(4-phenylpiperidin-1-yl)methanone : (scheme 2, entry 11, 3k)

Isolated yield = 41%; IR cm⁻¹: 2919, 2851, 1643, 1417, 1271, 1223, 1114, 1012, 757, 700. ¹H NMR $\delta(300 \text{ MHz}, \text{CDCl}_3)$ 7.28-7.33 (m, Ar, 2H), 7.18-7.23 (m, Ar, 3H), 3.81-3.87 (m, 2H), 3.7 (t, *J* = 4.5 Hz, 4H), 3.28 (t, *J* = 4.5 Hz, 4H), 2.89 (td, *J* = 2.4, 13 Hz, 2H), 2.67 (tt, *J* = 3.5, 11.8 Hz, 1H), 1.84-1.88 (m, 2H), 1.65-1.75 (m, 2H). ¹³C NMR $\delta(75 \text{ MHz CDCl}_3)$: 163.9, 145.4, 128.3, 126.6, 126.2, 66.5, 47.3, 42.7, 33. MS (ESI): m/z = 275 (M+H)⁺. HRMS ESI (M+H)⁺ m/z calcd for C₁₆H₂₃N₂O₂ (M+H)⁺ = 275.17540, found = 275.17499.



N-methyl-*N*-phenethylmorpholine-4-carboxamide : (scheme 2, entry 12, 3l)

Isolated yield = 40%; IR cm⁻¹: 2923, 1643, 1489, 1453, 1395, 1115, 1068, 749, 701. ¹H NMR $\delta(300 \text{ MHz}, \text{CDCl}_3)$ 7.27-7.31 (m, Ar, 2H), 7.18-7.23 (m, Ar, 3H), 3.6 (t, *J* = 4.9 Hz, 4H), 3.45 (t, *J* = 7.9 Hz, 2H), 3.11 (t, *J* = 4.9 Hz, 4H), 2.84-2.87 (m, 5H). ¹³C NMR $\delta(75 \text{ MHz}, \text{CDCl}_3)$: 164.2, 139, 128.6, 128.3, 126.1, 66.4, 51.3, 47.1, 36.6, 33.7. MS (ESI): m/z = 249 (M+H)⁺. HRMS ESI (M+H)⁺ m/z calcd for C₁₄H₂₁N₂O₂ (M+H)⁺ = 249.15975, found = 249.15926.



1,1-dimethyl-3-(1-phenylethyl)urea : (scheme 2, entry 13, 3m)

Isolated yield = 49% ; IR cm⁻¹: 2929, 1630, 1528, 1377, 1226, 761, 700. ¹H NMR δ (300 MHz, CDCl₃) 7.29-7.34 (m, Ar, 4H), 7.21-7.25 (m, 1H), 5.01 (p, *J* = 6.9 Hz, 1H), 4.6 (bs, 1H), 2.89 (s, 6H), 1.48 (d, *J* = 6.7 Hz, 3H). ¹³C NMR δ (75 MHz, CDCl₃): 157.5, 144.4, 128.4, 126.9, 125.9, 49.9, 36, 22.5. MS (ESI): m/z = 193 (M+H)⁺. HRMS ESI (M+H)⁺ m/z calcd for C₁₁H₁₇N₂O (M+H)⁺ = 193.13354, found = 193.13336.



3-cyclohexyl-1, 1-dimethylurea : (scheme 2, entry 14, 3n)

Isolated yield = 56%; IR cm⁻¹: 2930, 1625, 1534, 1388, 1359, 1217, 1030. ¹H NMR δ (300 MHz, CDCl₃) 4.18 (bs, 1H), 3.56-3.69 (m, 1H), 2.88 (s, 6H), 1.92-1.97 (m, 2H), 1.62-1.73 (m, 4H), 1.29-1.44 (m, 2H), 1.02-1.2 (m, 2H). ¹³C NMR δ (75 MHz, CDCl₃): 157.7, 49.3, 36, 34, 25.6, 25. MS (ESI): m/z = 171 (M+H)⁺. HRMS ESI (M+H)⁺ m/z calcd for C₉H₁₉N₂O (M+H)⁺ = 171.14919, found = 171.14879.



3-cyclooctyl-1, 1-dimethylurea : (scheme 2, entry 15, 30)

Isolated yield = 43%; IR cm⁻¹: 2921, 1634, 1522, 1340, 1327, 1201, 1021.¹H NMR δ (300 MHz, CDCl₃) 4.26 (m, 1H), 3.83-3.92 (m, 1H), 2.88 (s, 6H), 1.51-1.88 (m, 14H). ¹³C NMR δ (75 MHz, CDCl₃): 157.5, 50.3, 35.9, 32.9, 27, 25.3, 23.6. MS (ESI): m/z = 199 (M+H)⁺. HRMS ESI (M+H)⁺ m/z calcd for C₁₁H₂₃N₂O (M+H)⁺ = 199.18049, found = 199.18019.



N-(1-phenylethyl)morpholine-4-carboxamide : (scheme 2, entry 16, 3p)

Isolated yield = 33%; IR cm⁻¹: 2970, 2926, 1624, 1530, 1255, 1116, 995, 866, 762, 700, 564. ¹H NMR δ (300 MHz, CDCl₃) 7.32-7.37 (m, 4H), 7.22-7.29 (m, 1H), 5.02 (p, *J* = 6.7 Hz, 1H), 4.66 (bs, 1H), 3.67 (t, *J* = 4.7 Hz, 4H), 3.32-3.35 (m, 4H), 1.49 (d, *J* = 6.7 Hz, 3H). ¹³C NMR δ (75 MHz,CDCl₃): 156.9,

144.1, 128.4, 127, 125.9, 66.3, 49.9, 43.9, 22.4. MS (ESI): $m/z = 235 (M+H)^+$. HRMS ESI $(M+H)^+ m/z$ calcd for $C_{13}H_{19}N_2O_2 (M+H)^+ = 235.14410$, found = 235.14359.



N-cyclohexylmorpholine-4-carboxamide : (scheme 2, entry 17, 3q)

Isolated yield = 29%; IR cm⁻¹: 2929, 1614, 1538, 1454, 1414, 1274, 1252, 1109, 1074, 1027, 999, 855. ¹H NMR δ (300 MHz, CDCl₃) 4.26 (bs, 1H), 3.62-3.69 (m, 5H), 3.31 (t, *J* = 4.9 Hz, 4H), 1.95 (dd, *J* = 3.9, 12.9 Hz, 2H), 1.68-1.77 (m, 2H), 1.59-1.63 (m, 1H), 1.32-1.41 (m, 2H), 1.05-1.19 (m, 3H). ¹³C NMR δ (75 MHz ,CDCl₃): 157, 66.4, 49.3, 43.8, 33.8, 25.5, 24.9. MS (ESI): m/z = 213 (M+H)⁺. HRMS ESI (M+H)⁺ m/z calcd for C₁₁H₂₁N₂O₂ (M+H)⁺ = 213.15975, found = 213.15929.



Methyl 2-(3, 3-dimethylureido)-3-phenylpropanoate : (scheme 2, entry 18, 3r)

Isolated yield = 39%; IR cm⁻¹: 2930, 1740, 1639, 1527, 1453, 1382, 1202, 746, 701. ¹H NMR $\delta(300 \text{ MHz}, \text{CDCl}_3)$ 7.21 – 7.32 (m, 3H), 7.07 – 7.16 (m, 2H), 4.74 – 4.83 (m, 2H), 3.71 (s, 3H), 3.08 – 3.15 (m, 2H), 2.87 (bs, 6H). ¹³C NMR $\delta(75 \text{ MHz}, \text{CDCl}_3)$: 173.1, 157.3, 136.2, 129.1, 128.3, 126.8, 54.3, 52, 38.3, 35.9. MS (ESI): m/z = 251 (M+H)⁺. HRMS ESI (M+H)⁺ m/z calcd for C₁₃H₁₉N₂O₃ (M+H)⁺ = 251.13902, found = 251.13876.



Methyl2-(3, 3-dimethylureido)-3-methylbutanoate : (scheme 2, entry 19, 3s)

Isolated yield = 41%; IR cm⁻¹: 2937, 1744, 1632, 1502, 1435, 1352, 1242, 1085.¹H NMR δ (300 MHz, CDCl₃) 4.85 (bs, 1H), 4.42 – 4.46 (m, 1H), 3.73 (s, 3H), 2.94 (bs, 6H), 2.07 – 2.19 (m, 1H), 0.93 (q, *J* = 6.7 Hz, 6H). ¹³C NMR δ (75 MHz ,CDCl₃): 173.8, 157.8, 58.3, 51.8, 36, 31.1, 18.8, 17.7. MS (ESI): m/z = 203 (M+H)⁺. HRMS ESI (M+H)⁺ m/z calcd for C₉H₁₉N₂O₃ (M+H)⁺ = 203.13902, found = 203.13894.



N-methyl-4-phenylpiperidine-1-carboxamide : (scheme 2, entry 20, 3t)

Isolated yield = 48%; IR cm⁻¹: 2933, 1626, 1547, 1417, 1395, 1242, 1009, 756, 700. ¹H NMR δ (300 MHz, CDCl₃) 7.28-7.33 (m, Ar, 2H), 7.18-7.23 (m, Ar, 3H), 4.6 (bs, 1H), 4.06-4.1 (m, 2H), 2.82-2.92 (m, 5H), 2.66 (tt, *J* = 3.5, 12 Hz, 1H), 1.82-1.87 (m, 2H), 1.65 (qd, *J* = 3.9, 12.4 Hz, 2H). ¹³C NMR δ (75 MHz, CDCl₃): 158.3, 145.4, 128.4, 126.6, 126.2, 44.5, 42.5, 32.9, 27.5. MS (ESI): m/z = 219 (M+H)⁺. HRMS ESI (M+H)⁺ m/z calcd for C₁₃H₁₉N₂O (M+H)⁺ = 219.14919, found = 219.14874.



1,3-dimethly-1-phenethylurea : (scheme 2, entry 21, 3u)

Isolated yield = 47%; IR cm⁻¹: 2929, 1630, 1536, 1379, 1305, 1235, 1146, 1078, 1030, 979, 748, 700. ¹H NMR δ (300 MHz, CDCl₃) 7.18-7.31 (m, Ar, 5H), 4.43 (bs, 1H), 3.47 (t, *J* = 7.1 Hz, 2H), 2.79-2.84 (m, 5H), 2.72 (d, *J* = 4.5 Hz). ¹³C NMR δ (75 MHz, CDCl₃): 158.7, 139.1, 128.6, 128.3, 126.1, 50.8, 34.5, 34.4, 27.4. MS (ESI): m/z = 193 (M+H)⁺. HRMS ESI (M+H)⁺ m/z calcd for C₁₁H₁₇N₂O (M+H)⁺ = 193.13354, found = 193.13330.



4-benzyl-N-methylpiperidine-1-carboxamide : (scheme 2, entry 22, 3v)

Isolated yield = 52% ; IR cm⁻¹: 2918, 1624, 1546, 1417, 1396, 1253, 1149, 1032, 961, 746, 700. ¹H NMR $\delta(300 \text{ MHz}, \text{CDCl}_3)$ 7.25-7.30 (m, Ar, 2H), 7.16-7.21 (m, Ar, 1H), 7.11-7.14 (m, Ar, 2H), 4.54 (bs, 1H), 3.87-3.92 (m, 2H), 2.78 (d, *J* = 3.7 Hz, 3H), 2.69 (td, *J* = 2.2, 12.8 Hz, 2H), 2.53 (d, *J* = 6.7 Hz, 2H), 1.61-1.72 (m, 3H), 1.1-1.23 (m, 2H). ¹³C NMR $\delta(75 \text{ MHz}, \text{CDCl}_3)$: 158.4, 139.9, 128.9, 128, 125.8, 44, 42.9, 37.9, 31.6, 27.4. MS (ESI): m/z = 233 (M+H)⁺. HRMS ESI (M+H)⁺ m/z calcd for C₁₄H₂₁N₂O (M+H)⁺ = 233.16484, found = 233.16444.



3-(2-acetylphenyl)-1, 1-dimethylurea : (scheme 3, entry 1, 5a)

Isolated yield = 31% ; IR cm⁻¹: 2927, 1677, 1644, 1586, 1530, 1451, 1362, 1313, 1242, 1180, 1163, 959, 758, 695. ¹H NMR δ (300 MHz, CDCl₃) 11.42 (bs, 1H), 8.65 (dd, *J* = 0.7, 8.4Hz, 1H), 7.86 (dd, *J* = 1.5, 8.1 Hz, 1H), 7.51 (td, *J* = 1.3, 8.4 Hz, 1H), 6.99 (td, *J* = 1.1, 8.1 Hz), 3.09 (bs, 6H), 2.66 (s, 3H). ¹³C NMR δ (75 MHz CDCl₃): 202.8, 155.6, 143.2, 135, 131.5, 120.1, 119.5, 36.2, 29.5. MS (ESI): m/z = 229 (M+Na)⁺. HRMS ESI (M+Na)⁺ m/z calcd for C₁₁H₁₄N₂O₂Na (M+Na)⁺ = 229.09475, found = 229.09441.



3-(2-benzoylphenyl)-1, 1-dimethylurea : (scheme 3, entry 2, 5b)

Isolated yield = 38% ; IR cm⁻¹: 2928, 1678, 1629, 1582, 1523, 1447, 1361, 1255, 1176, 938, 752, 700, 644. ¹H NMR δ (300 MHz, CDCl₃) 10.77 (bs, 1H), 8.56 (dd, *J* = 1.1, 8.6 Hz, 1H), 7.65 – 7.67 (m, 2H), 7.45 – 7.61 (m, 5H), 6.95 (td, *J* = 1.1, 8.1 Hz, 1H), 3.11 (bs, 6H). ¹³C NMR δ (75 MHz, CDCl₃): 200.3, 155.5, 143.1, 139, 134.5, 133.9, 131.9, 129.5, 128.1, 121.6, 120.3, 119.9, 36.2. MS (ESI): m/z = 269 (M+H)⁺. HRMS ESI (M+H)⁺ m/z calcd for C₁₆H₁₇N₂O₂ (M+H)⁺ = 269.12845, found = 269.12799.



3-(2-benzoyl-4-chlorophenyl)-1, 1-dimethylurea : (scheme 3, entry 3, 5c)

Isolated yield = 39% ; IR cm⁻¹: 2929, 1677, 1634, 1578, 1512, 1397, 1362, 1240, 1175, 950, 832, 747, 701. ¹H NMR δ (300 MHz, CDCl₃) 10.6 (bs, 1H), 8.54 - 8.57 (m, 1H), 7.59 - 7.68 (m, 3H), 7.47 - 7.53 (m, 4H), 3.09 (bs, 6H). ¹³C NMR δ (75 MHz, CDCl₃): 199, 155.2, 141.6, 138.3, 134.2, 132.7, 129.5, 128.4, 124.9, 122.7, 122, 36.2. MS (ESI): m/z = 303 (M+H)⁺. HRMS ESI (M+H)⁺ m/z calcd for C₁₆H₁₆ClN₂O₂ (M+H)⁺ = 303.08948, found = 303.08905.



3-(2-benzoyl-4-nitrophenyl)-1, 1-dimethylurea : (scheme 3, entry 4, 5d)

Isolated yield = 35% ; IR cm⁻¹: 2925, 2854, 1694, 1623, 1508, 1332, 1252, 959, 750, 697, 553. ¹H NMR δ (300 MHz, CDCl₃) 11.21 (bs, 1H), 8.83 (d, *J* = 9 Hz, 1H), 8.51 (d, *J* = 3 Hz, 1H), 8.38 (dd, *J* = 3, 9.8 Hz, 1H), 7.64 – 7.69 (m, 3H), 7.55 (t, *J* = 6.7 Hz, 2H), 3.15 (bs, 6H). ¹³C NMR δ (75 MHz, CDCl₃): 199, 154.4, 148.6, 139.7, 137.8, 133, 129.6, 129.1, 128.7, 120.2, 120.1, 36.4. MS (ESI): m/z = 314 (M+H)⁺. HRMS ESI (M+H)⁺ m/z calcd for C₁₆H₁₆N₃O₄ (M+H)⁺ = 314.11353, found = 314.11322.



Methyl 4-chloro-1-(dimethylcarbamoyl)-1H-indole-2-carboxylate : (scheme 3, entry 5, 5e)

Isolated yield = 37%; IR cm⁻¹: 2929, 1708, 1530, 1441, 1390, 1245, 1199, 1060, 763, 729. ¹H NMR δ (300 MHz, CDCl₃) 7.66 (bs, 1H), 7.32 – 7.34 (m, 1H), 7.24 – 7.27 (m, 2H), 4.38 (q, *J* = 6.9 Hz, 2H), 3.25 (bs, 3H), 2.79 (bs, 3H), 1.39 (t, *J* = 6.9 Hz, 3H). ¹³C NMR δ (75 MHz, CDCl₃): 160.4, 152.7, 135.3, 129.1, 127.4, 126.5, 121.8, 112.2, 110.9, 61.2, 37.7, 36.8, 14.1. MS (ESI): m/z = 295 (M+H)⁺. HRMS ESI (M+H)⁺ m/z calcd for C₁₄H₁₆ClN₂O₃ (M+H)⁺ = 295.08440, found = 295.08401.



Methyl 1-(dimethylcarbamoyl)-*1H*-pyrrole-2-carboxylate : (scheme 3, entry 6, 5f)

Isolated yield = 40%; IR cm⁻¹: 2925, 1704, 1442, 1393, 1292, 1236, 1141, 1093, 1060, 755. ¹H NMR $\delta(300 \text{ MHz}, \text{CDCl}_3) 6.95 - 6.98 \text{ (m, 2H)}, 6.26 - 6.29 \text{ (m, 1H)}, 3.83 \text{ (s, 3H)}, 3.17 \text{ (bs, 3H)}, 2.71 \text{ (bs, 3H)}.$ 3H). ¹³C NMR $\delta(75 \text{ MHz}, \text{CDCl}_3)$: 160.4, 153.4, 125, 122.5, 117.5, 110.2, 51.5, 37.7, 36.6. MS (ESI): m/z = 197 (M+H)⁺. HRMS ESI (M+H)⁺ m/z calcd for C₉H₁₃N₂O₃ (M+H)⁺ = 197.09207, found = 197.09167.

5. Copies of ¹H NMR and ¹³C NMR spectra : compound 3a





Compound 3b



Compound 3d

Compound 3e

Compound 3f

Compound 3g

Compound 3h

Compound 3i

Compound 3j

Compound 3k

Compound 31

Compound 3m

Compound 3n

Compound 3o

Compound 3p

Compound 3q

Compound 3r

Compound 3s

Compound 3t

Compound 3u

Compound 3v

Compound 5a

Compound 5b

Compound 5c

Compound 5d

Compound 5e

Compound 5f

HPLC data of compound 3r :

A : reaction between L –Phenyl Alanine Methyl Ester and DMF

	4.512	148241	1.37	202
	5.237	10693378	98.63	204
Totals		10841619	100.00	

B : Reaction between **D** – Phenyl Alanine Methyl Ester and DMF

C : Mixture of L + D

Name	Retention Time	Area	Area Percent	Lambda Max
	4.661 5.248	6411264 7394918	46.44 53.56	203 203
Totals		13806182	100.00	

HPLC data of compound 3s :

A: (reaction between L-Valine Methyl Ester and DMF)

B : (reaction between **D** – Valine Methyl Ester and **DMF**)

4: 210 nm, 8 nm				
	ne Retention	Area	Area	Lambda
	Time		Percent	Max
1	7.467	205204	1.56	203
2	8.128	12979150	98.44	203
Totals				
		13184354	100.00	

C : (mixture of L + D)

4: 210 nm, 8 nm					
	Name	Retention	Area	Area	Lambda
		Time		Percent	Max
1		7.595	359566	2.02	202
2		8.128	8781389	49.32	204
3		8.789	8662332	48.66	204
Totals					
			17803287	100.00	